Phase I/II Hepatocellular Carcinoma (HCC) Clinical Trial

Bavituximab and Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Enrollment is open in a Phase I/II open-label trial to evaluate bavituximab and sorafenib in patients with advanced HCC. The open-label trial will enroll up to 50 patients in the United States.

Primary Endpoint Maximum tolerated dose (MTD), time to progression (TTP)
Secondary Endpoints Response rate (ORR), progression free-survival (PFS), overall survival (OS), safety and tolerability

For additional information and a list of clinical sites open for enrollment, please visit the ClinicalTrials.gov page for this trial

Phase Ib Front-Line Non-Small Cell Lung Cancer (NSCLC) Clinical Trial

Bavituximab with Pemetrexed and Carboplatin in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Enrollment is open in a Phase I clinical trial to evaluate bavituximab (PS-targeting monoclonal antibody) combined with pemetrexed and carboplatin in patients with locally advanced or metastatic NSCLC. The open-label dose escalation trial will enroll up to 25 patients.

Primary Endpoints Safety, dose-limiting toxicity (DLT) and recommended Phase II dose of bavituximab in combination with carboplatin and pemetrexed in advanced non-squamous NSCLC
Secondary Endpoints Overall response rate (ORR) measured by RECIST criteria, progression-free survival (PFS) and overall survival (OS) and exploratory biomarkers

For additional information and a list of clinical sites open for enrollment, please visit the ClinicalTrials.gov page for this trial

Phase I Rectal Adenocarcinoma Clinical Trial

Bavituximab with Capecitabine and Radiation in Stage II/III Rectal Adenocarcinoma

Enrollment is open in a Phase I open-label trial to evaluate bavituximab with capecitabine and radiation in patients with stage II or III rectal adenocarcinoma. The trial will enroll up to 18 patients.

Primary Endpoints Safety, feasibility and tolerability of combining bavituximab to a standard platform of capecitabiner and radiation therapy.
Secondary Endpoints Assessment of any anti-tumor activity by objective response as determined by MR imaging and histopathological response in patients

For additional information please visit the ClinicalTrials.gov page for this trial

Tumor Imaging Clinical Trial

Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors

Enrollment is open in a clinical trial to evaluate I-124 PGN650 (radiolabeled PS-targeting monoclonal antibody fragment) in patients with advanced solid tumors. The trial will enroll up to 12 patients.

Primary Endpoint Radiation dosimetry

Secondary Endpoints Tumor imaging, safety

For additional information please visit the ClinicalTrials.gov page for this trial

Download imaging trial fact sheet

If you are a health care provider interested in referring a patient or learning more about our ongoing clinical trials, please visit www.peregrinetrials.com, or send an e-mail to Peregrine Pharmaceuticals at   This e-mail address is being protected from spambots. You need JavaScript enabled to view it

If you are a patient interested in participating in one of our trials, please have your personal physician send an email correspondence to Peregrine.